{"entity":{"id":"nct05855200","kind":"trial","name":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","aka":[],"tldr":"A phase 3 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, now recruiting.","summary":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer is a phase 3 interventional study registered as NCT05855200 by GlaxoSmithKline, with 892 participants planned, started 2023-08-01 and due to reach its primary completion in 2029-03-19. Interventions recorded: Dostarlimab, CAPEOX and FOLFOX.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05855200","url":"https://clinicaltrials.gov/study/NCT05855200"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["dostarlimab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05855200","phase":"3","setting":"A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","sponsor":"GlaxoSmithKline","enrolled":892,"outcomes":[]},"route":"/trials/nct05855200/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}